Jpmorgan Chase & CO Akero Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 332,383 shares of AKRO stock, worth $17.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
332,383
Previous 528,207 37.07%
Holding current value
$17.8 Million
Previous $14.7 Million 8.44%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$21.87 - $57.56 $4.28 Million - $11.3 Million
-195,824 Reduced 37.07%
332,383 $13.5 Million
Q4 2024

Feb 12, 2025
BUY
$26.75 - $35.28 $1.07 Million - $1.42 Million
40,161 Added 8.23%
528,207 $14.7 Million
Q3 2024

Dec 26, 2024
SELL
$21.45 - $29.34 $1.16 Million - $1.59 Million
-54,221 Reduced 10.0%
488,046 $14 Million
Q3 2024

Nov 08, 2024
SELL
$21.45 - $29.34 $1.16 Million - $1.59 Million
-54,221 Reduced 10.0%
488,046 $14 Million
Q2 2024

Dec 26, 2024
BUY
$18.31 - $24.62 $992,786 - $1.33 Million
54,221 Added 11.11%
542,267 $12.7 Million
Q2 2024

Aug 12, 2024
BUY
$18.31 - $24.62 $3.97 Million - $5.34 Million
216,868 Added 66.65%
542,267 $12.7 Million
Q1 2024

Dec 26, 2024
SELL
$17.76 - $31.18 $2.89 Million - $5.07 Million
-162,647 Reduced 33.33%
325,399 $8.22 Million
Q1 2024

May 10, 2024
BUY
$17.76 - $31.18 $3.06 Million - $5.38 Million
172,521 Added 112.85%
325,399 $8.22 Million
Q4 2023

Dec 26, 2024
SELL
$11.38 - $50.33 $3.81 Million - $16.9 Million
-335,168 Reduced 68.68%
152,878 $3.57 Million
Q4 2023

Feb 12, 2024
SELL
$11.38 - $50.33 $6.39 Million - $28.3 Million
-561,700 Reduced 78.61%
152,878 $3.57 Million
Q3 2023

Nov 14, 2023
BUY
$41.19 - $52.25 $15.5 Million - $19.7 Million
377,258 Added 111.84%
714,578 $36.1 Million
Q2 2023

Aug 11, 2023
BUY
$36.89 - $56.88 $4.64 Million - $7.16 Million
125,852 Added 59.51%
337,320 $15.7 Million
Q1 2023

May 18, 2023
BUY
$37.27 - $50.24 $995,332 - $1.34 Million
26,706 Added 14.45%
211,468 $8.09 Million
Q1 2023

May 11, 2023
BUY
$37.27 - $50.24 $53,929 - $72,697
1,447 Added 0.79%
184,762 $7.07 Million
Q4 2022

Feb 13, 2023
SELL
$33.44 - $54.8 $1.75 Million - $2.86 Million
-52,214 Reduced 22.17%
183,315 $10 Million
Q3 2022

Nov 14, 2022
BUY
$10.15 - $34.05 $7,125 - $23,903
702 Added 0.3%
235,529 $8.02 Million
Q2 2022

Aug 11, 2022
BUY
$8.0 - $15.01 $1.51 Million - $2.84 Million
188,960 Added 411.97%
234,827 $2.22 Million
Q1 2022

May 11, 2022
SELL
$12.97 - $22.26 $25,382 - $43,562
-1,957 Reduced 4.09%
45,867 $651,000
Q4 2021

Feb 10, 2022
SELL
$19.87 - $26.24 $19,989 - $26,397
-1,006 Reduced 2.06%
47,824 $1.01 Million
Q3 2021

Nov 12, 2021
BUY
$18.65 - $25.46 $910,679 - $1.24 Million
48,830 New
48,830 $1.09 Million

Others Institutions Holding AKRO

# of Institutions
297
Shares Held
92.2M
Call Options Held
1.72M
Put Options Held
901K
View Full List

About Akero Therapeutics, Inc.

AKRO Quotes by TradingView
  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.49B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email